Corbus Pharmaceuticals (CRBP) shares slumped 10% in recent trading Friday despite reporting what it described as encouraging data from the "Western" clinical trial of its CRB-701 anti-body drug conjugate.
A total of 26 patients with metastatic urothelial cancer and other solid tumors associated with Nectin-4 expression were evaluable at December 2024 data cut point in the US and UK study.
The phase 1 Western dose escalation study's results mirrored those from the China study in terms of safety, tolerability, and pharmacokinetics, the company said. No dose-limiting adverse events were reported from both studies, it said.
However, Corbus reported one response in four metastatic urothelial cancer patients dosed in the Western study, compared with the China study's 44% involving nine patients.
The company on Friday presented the data from the Western study at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Price: 8.53, Change: -0.95, Percent Change: -10.02
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。